Justis Ehlers, MD, FASRS

Justis Ehlers discusses promising results from the HELIOS trial, revealing a novel treatment for diabetic retinopathy that may reduce treatment frequency.

Justis Ehlers, MD, FASRS, presented "PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy," during the 2025 ASRS meeting held in Long Beach, California.